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A B S T R A C T   
We have applied a combination of venomics, in vivo neutralization assays, and in vitro third-generation antivenomics analysis to assess the preclinical efficacy of the 
monospecific anti-Macrovipera lebetina turanica (anti-Mlt) antivenom manufactured by Uzbiopharm® (Uzbekistan) and the monospecific anti-Vipera berus berus 
antivenom from Microgen® (Russia) against the venom of Dagestan blunt-nosed viper, Macrovipera lebetina obtusa (Mlo). Despite their low content of homologous 
(anti-Mlt, 5–10%) or para-specific (anti-Vbb, 4–9%) F(ab’)2 antibody fragments against M. l. obtusa venom toxins, both antivenoms efficiently recognized most 
components of the complex venom proteome’s arsenal, which is made up of toxins derived from 11 different gene families and neutralized, albeit at different doses, 
key toxic effects of M. l. obtusa venom, i.e., in vivo lethal and hemorrhagic effects in a murine model, and in vitro phospholipase A2, proteolytic and coagulant ac-
tivities. The calculated lethality neutralization potencies for Uzbiopharm® anti-Mlt and anti-Vbb Microgen® antivenoms were 1.46 and 1.77 mg/mL, indicating that 
1 mL of Uzbiopharm® and Microgen® antivenoms may protect mice from 41 to 50 LD50s of Mlo venom, respectively. The remarkable degree of conservation of 
immunogenic determinants between species of the clades of European and Oriental viper, which evolved geographically segregated since the early Miocene, suggests 
an eventual window of opportunity for the treatment of envenomings by Eurasian snakes. Clearly, the rational use of heterologous antivenoms requires establishing 
their para-specificity landscapes. This paper illustrates the analytical power of combining in vitro and in vivo preclinical quantitative assays toward this goal.   
1. Introduction 
Old World vipers (subfamily Viperinae within family Viperidae) are 
a group of venomous snakes endemic to Europe, Africa and Asia. Also 
known as true adders or viperines, these Eurasian snakes (extant genera 
Eristicophis, Pseudocerastes, Vipera, Macrovipera, Montivipera and Daboia) 
had their roots in a basal segregation of the Vipera sensu lato group 
(Laurenti, 1768) on three landmasses separated by the Mediterranean 
and Paratethys Seas, Europe, the Middle East and North Africa, during 
the early Miocene period (23.3–16.3 million years ago) (R€ogl and 
Steininger, 1983; Szyndlar and Rage, 1999; Lenk et al., 2001; Garrigues 
et al., 2005). Present-day Old World snakes are distributed in a wide 
variety of habitats from North Africa to just within the Arctic Circle and 
from Great Britain to Pacific Asia (Mallow et al., 2003; Phelps, 2010). 
During the last decades the phylogeny of the Vipera sensu lato poly-
phyletic group has undergone constant revision and divisions by a 
number of authors. Three major clades have been identified (Lenk et al., 
2001; Garrigues et al., 2005), the European vipers (De Smedt, 2006; 
Kreiner, 2007); the oriental vipers, represented by i) the blunt-nosed 
Macrovipera lebetina subspecies lebetina (Linnaeus, 1758), turanica 
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(Chernov, 1940) (Terentiev and Chernov, 1940), obtusa (Dwigubsky, 
1832), cernovi (Chikin and Shcherbak, 1992), and transmediterranea 
(Nilson and Andr�en, 1988); M. schweizerei (Werner, 1935); and the 
recently described Macrovipera razii sp. n., with at least seven known 
representatives from central and southern Iran (Oraie et al., 2018), 
within the genus Macrovipera (Reuss, 1927; Herrmann et al., 1992); ii) 
the Mountain vipers of the Montivipera xanthina-raddei complex (Nilson 
et al.,1999); and iii) a group of Asian and North African vipers within 
genus Daboia (Gray, 1842). 
The Dagestan blunt-nosed viper Macrovipera lebetina obtusa (Dwi-
gubsky, 1832) is endemic to Asia. Having by far the widest range in 
central Asia, this large stout-bodied species, which can reach lengths of 
up to 1.7 m, is found in dry and well vegetated rocky mountainous areas 
between 1000 and 2500 m elevation from central Turkey through Syria, 
Lebanon, Iraq, northern Jordan, the Caucasus region (incl. Armenia), 
Azerbaijan, Dagestan, western and northwestern Iran, southern 
Afghanistan, Pakistan and the Kashmir region (Mallow et al., 2003; 
Oraie et al., 2018). In Pakistan, M. l. obtusa is restricted to the western 
highlands, and is allopatric with Daboia russelii in the Indus River valley 
(Khan, 1983). Crepuscular and nocturnal, but often abroad during 
daylight on overcast days, M.l. obtusa climb and forage in bushes. Adults 
feed primarily on small mammals, whereas young take mainly lizards 
(Phelps, 2010). 
The venom of the Dagestan blunt-nosed viper, a WHO category 2 
species (Warrell, 2010), is highly potent. A mean dry venom yield of 48 
mg per snake and intravenous (i.v.) LD50 of 12–18 μg/18 g mouse body 
weight have been reported (Latifi, 1984; Kurtovi�c et al., 2014). Human 
envenomings by M. l. obtusa cause life-threating systemic hemodynamic 
disturbances, reduced functionality of the kidneys, and ischemia at the 
bite site (Schweiger, 1983; G€oçmen et al., 2006; Sharma et al., 2008). 
Acute kidney injury is not common and if happens, is due to hypoten-
sion, and deposit of hemoglobin, myoglobin, and fibrin in the renal tu-
bules causing acute tubular necrosis (Burdmann et al., 1993). However, 
information on the epidemiology of envenomings by M. l. obtusa across 
its distribution is scarce (Chippaux, 2012; Dehghani et al., 2014; Zamani 
et al., 2016) or non-existent. 
Treatment of snakebites envenomings is critically dependent on the 
availability of effective antivenoms. This study was designed to assess a 
comparative preclinical efficacy of the monospecific anti-M. lebetina 
turanica (anti-Mlt) antivenom manufactured by Uzbiopharm® (Uzbeki-
stan) and the monospecific anti-Vipera berus berus antivenom from 
Microgen® (Russia) to neutralize key toxic effects of M. l. obtusa venom, 
i.e., lethal, defibrinogenetic, hemorrhagic, phospholipase A2 activity, 
proteolytic, and coagulant, by combination of in vivo neutralization as-
says and in vitro third-generation antivenomics analysis. 
2. Materials and methods 
2.1. Venom and antivenoms 
Venom from Macrovipera lebetina obtusa (Mlo) was pooled from 10 
adult individuals between 80 and 110 cm in length and older than 3 
years, of both sexes, collected, during the day in spring and autumn and 
in summer nights, in different regions of the Republic of Dagestan 
(Russian Federation). Venom was air-dried at room temperature and 
stored at   8 �C until used. Monospecific anti-M. lebetina turanica anti-
venom was manufactured by Uzbiopharm® (Tashkent, Uzbekistan) 
(batch 23, expiry date March 2020; 98 � 4 mg F(ab’)2/mL, 9.4 mL/ 
ampoule). The monospecific anti-Vipera berus berus antivenom was from 
Microgen® (Moscow, Russia) (Al-Shekhadat et al., 2019) (batches C43 
and C37, expiry dates June 2020 and January 2021, respectively; 
85–110.5 mg F(ab’)2/mL, 1.1–1.3 mL/ampoule). 
2.2. Animals 
CD-1 mice (18–20 g body weight) were used throughout the study. 
The protocols involving the use of mice were approved by the Institu-
tional Committee for the Care and Use of Laboratory Animals (CICUA) of 
Universidad de Costa Rica (Act 82–2008, date of the approval: 18 
September 2008). 
2.3. Proteomic characterization of Macrovipera lebetina obtusa venom 
Crude air-dried at room temperature venom was dissolved in 0.05% 
trifluoroacetic acid (TFA) and 5% acetonitrile (ACN) to a final concen-
tration of 15 mg/mL. Insoluble material was removed by centrifugation 
in an Eppendorf centrifuge at 13,000�g for 10 min at room temperature, 
and the proteins contained in 40 μL (600 μg) were separated by RP-HPLC 
using a Agilent LC 1100 High Pressure Gradient System equipped with a 
Teknokroma Europa C18 (25 cm � 4 mm, 5 μm particle size, 300 Å pore 
size) column and a DAD detector. The column was developed at a flow 
rate of 1.0 mL/min with a linear gradient of 0.1% TFA in MilliQ® water 
(solution A) and 0.1% TFA in acetonitrile (solution B), isocratic (5% B) 
for 5 min, followed by 5–25% B for 10 min, 25–45% B for 60 min, and 
45–70% B for 10 min. Protein detection was carried out at 215 nm with a 
reference wavelength of 400 nm. Fractions were collected manually 
across the entire elution range, dried in a vacuum centrifuge (Savant™, 
ThermoFisher Scientific), and redissolved in MilliQ® water. Molecular 
masses of the purified proteins were estimated by non-reduced and 
reduced SDS-PAGE (on 15% polyacrylamide gels). 
For SDS-PAGE analysis RP-HPLC sample aliquots were mixed with ¼ 
volume of 4x sample buffer (0.25M Tris-HCl pH 6.8, 8% SDS, 30% 
glycerol, 0.02% bromophenol blue, with or without 10% 2-mercaptoe-
thanol) and heated at 85 �C for 15 min, run under reducing condi-
tions, and the gels were stained with Coomassie Brilliant Blue G-250. 
Protein bands of interest were excised and subject to in-gel disulphide 
bond reduction (10 mM dithiothreitol, 30 min at 65 �C) and sulphydryl 
group alkylation (50 mM iodoacetamide, 2h in the dark at room tem-
perature), followed by overnight digestion with sequencing-grade 
trypsin (66 ng/μL in 25 mM ammonium bicarbonate, 10% ACN; 0.25 
μg/sample), using a Genomics Solution ProGest™ Protein Digestion 
Workstation. Tryptic digests were dried in a vacuum centrifuge (SPD 
SpeedVac®, ThermoSavant), redissolved in 14 μL of 5% ACN containing 
0.1% formic acid, and 7 μL submitted to LC-MS/MS. Tryptic peptides 
were separated by nano-Acquity UltraPerformance LC® (UPLC®) using 
a BEH130 C18 (100 μm � 100mm, 1.7 μm particle size) column in-line 
with a Waters SYNAPT G2 High Definition Mass Spectrometry System. 
The flow rate was set to 0.6 μL/min and the column was developed with 
a linear gradient of 0.1% formic acid in water (solution A) and 0.1% 
formic acid in ACN (solution B), isocratically 1% B for 1 min, followed 
by 1–12% B for 1min, 12–40% B for 15min, 40–85% B for 2min. Doubly 
and triply charged ions were selected for CID-MS/MS. Fragmentation 
spectra were interpreted i) manually (de novo sequencing), ii) using the 
on-line form of the MASCOT Server (version 2.6) at http://www. 
matrixscience.com against the last update (Release 234 of October 
15th, 2019) of NCBI non-redundant database, and iii) processed in 
Waters Corporation’s ProteinLynx Global SERVER 2013 version 2.5.2. 
(with Expression version 2.0). The following search parameters were 
used: Taxonomy: bony vertebrates; Enzyme: trypsin (two missed 
cleavage allowed); MS/MS mass tolerance was set to � 0.6 Da; carba-
midomethyl cysteine and oxidation of methionine were selected as fixed 
and variable modifications, respectively. All matched MS/MS data were 
manually checked. Peptide sequences assigned by de novo MS/MS were 
matched to homologous proteins available in the NCBI non-redundant 
protein sequences database using the online BLASTP program (Alt-
schul et al., 1990) at https://blast.ncbi.nlm.nih.gov/Blast.cgi. The 
relative abundances of the chromatographic peaks obtained by 
reverse-phase HPLC fractionation of the whole venom were calculated 
as “percentage of total peptide bond concentration in the peak” by 
dividing the peak area by the total area of the chromatogram (Calvete, 
2014; Eichberg et al., 2015). For chromatographic peaks containing 
single components (by SDS-PAGE and/or MS), this figure is a good 
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estimate of the % by weight (g/100 g) of the pure venom component 
(Calder�on-Celis et al., 2017). When more than one venom protein was 
present in a reverse-phase fraction, their proportions (percentage of 
total protein band area) were estimated by densitometry of 
Coomassie-stained SDS-polyacrylamide gels using MetaMorph® Image 
Analysis Software (Molecular Devices). Conversely, the relative abun-
dances of different proteins contained in the same SDS-PAGE band were 
estimated based on the mean relative ion intensity of the three most 
abundant peptide ions associated with each protein by MS/MS analysis. 
The analytical variability associated with this label-free approach has 
been estimated within a relative error of 15% (Silva et al., 2006). The 
relative abundances of the protein families present in the venom were 
calculated as the ratio of the sum of the percentages of the individual 
proteins from the same toxin family to the total area of venom protein 
peaks in the reverse-phase chromatogram. 
2.4. Toxic and enzymatic venom activities in mice and their 
neutralization assays 
2.4.1. Lethality 
For the estimation of the Median Lethal Dose (LD50), groups of five 
CD-1 mice received by the intraperitoneal (i.p.) route increasing doses of 
venom (15 μg–240 μg per mouse) dissolved in a volume of 0.5 mL 0.12 M 
NaCl, 0.04 M phosphate, pH 7.2 (PBS). Deaths occurring within 48 h 
were recorded and the LD50 was estimated by probits as the minimum 
amount of venom causing the death of 50% of the mice injected, with 
95% confidence limits (Finney, 1947; Al-Shekhadat et al., 2019). For the 
neutralization of lethality, mixtures containing a fixed dose of venom 
and various dilutions of antivenom were prepared, and incubated at 37 
�C for 30 min. Aliquots of 0.5 mL of each mixture, containing a dose of 
venom corresponding to 4 LD50s, were then injected intraperitoneally (i. 
p.) into groups of five mice. Mixtures corresponded to various ratios of 
mg venom/mL antivenom. A control group was injected with 4 LD50s of 
venom incubated with PBS instead of antivenom. Deaths occurring 
during 48 h were recorded, and the neutralizing ability of antivenom 
was expressed as the Median Effective Dose (ED50), i.e. the venom/-
antivenom ratio at which half of the population of injected mice is 
protected, estimated by Probits. (Finney, 1947). 
Antivenom potency (P) is the amount of venom (mg) completely 
neutralized per mL of antivenom. P was calculated using formula P ¼
[(n-1)/ED50] � LD50, where “n" is the number of median lethal doses 
(LD50s) used as challenge dose to determine the antivenoms median 
effective dose, ED50. For the calculation of P, LD50 and ED50 are 
expressed, respectively, as (mg venom/mouse) and (mL of antivenom 
that protect 50% of the mice population inoculated with n x LD50). In the 
calculation of P, (n-1) x LD50 is used instead of the total amount of 
venom, n x LD50, because at the endpoint of the neutralization assay, one 
LD50 remains unneutralized and causes the death of 50% of mice (Araujo 
et al., 2008; Morais et al., 2010). 
2.4.2. Hemorrhagic activity 
To assess the hemorrhagic activity of venoms, groups of three CD-1 
mice received an intradermal (i.d.) injection, in the ventral abdominal 
region, of 0.1 mL of PBS containing several dilutions of venom (from 
0.12 μg to 2.0 μg). Mice were sacrificed by CO2 inhalation 2 h after in-
jection, the skin was removed, and the area of the hemorrhagic lesion in 
the inner side of the skin was measured. The Minimum Hemorrhagic 
Dose (MHD) corresponds to the dose of venom that induces a hemor-
rhagic area of 10 mm diameter (Guti�errez et al., 1985). For the assess-
ment of the neutralizing capacity of antivenoms, mixtures containing a 
fixed dose of venom and various dilutions of antivenom were prepared, 
and incubated at 37 �C for 30 min (Guti�errez et al., 1985). Then, aliquots 
of 0.1 mL of each mixture, containing a dose of venom corresponding to 
10 Minimum Hemorrhagic Doses (MHDs), were injected i. d. into groups 
of three mice, as described. Mixtures corresponded to various ratios of 
mg venom/mL antivenom. A control group of mice was injected with the 
same dose of venom incubated with PBS instead of antivenom. Mice 
were sacrificed as described 2 h after injection, and the area of the 
hemorrhagic lesion was measured. Neutralizing ability was expressed as 
the Median Effective Dose (ED50), corresponding to the ratio venom/-
antivenom at which the diameter of the hemorrhagic spot is reduced by 
50% when compared to the diameter of the hemorrhagic lesion in mice 
injected with venom incubated with no antivenom (Guti�errez et al., 
1985). 
2.4.3. Defibrinogenating activity 
Various amounts of venom dissolved in 200 μL of PBS were injected i. 
v. to groups of three mice following the method described by Gen�e and 
coworkers (1989). One hour after injection, mice were bled from the 
orbital plexus under ether anaesthesia, the blood was placed in dry glass 
tubes and left undisturbed for 2 h at 22–25 �C. Thereafter, the tubes were 
gently tilted and the presence, or absence, of clots was recorded. The 
Minimum Defibrinogenating Dose (MDD) corresponded to the minimum 
dose of venom that rendered blood unclottable in all mice tested. 
2.5. In vitro toxic and enzymatic venom activities and their neutralization 
assays 
2.5.1. Coagulant activity 
Coagulant activity of Mlo venom was determined based on the 
turbidimetric assay described (O’Leary and Isbister, 2010) as modified 
by S�anchez et al. (2018). Briefly, different amounts of venom, dissolved 
in 100 μL TBS (25 mM Tris-HCl, 137 mM NaCl, 3.4 mM KCl, pH 7.4) 
were added in triplicate to wells in a 96-well plate and incubated for 5 
min at 37 �C in a microplate reader (Cytation 3 Imaging Reader, Bio-
Tek). Then, 4 μL of 0.4 M CaCl2 was added to 100 μL of human citrated 
plasma previously incubated at 37 �C, and this mixture was added 
immediately to each venom-containing well using a multichannel 
pipette. Samples were mixed for 5 s shaking step, and the absorbance at 
340 nm was monitored every 30 s over 15 min. The increase in absor-
bance reflects the formation of a clot. Coagulant activity was expressed 
as the Minimum Coagulant Dose (MCD), corresponding to the minimum 
dose of venom that induces a change in absorbance of 0.01 units within 
1 min. Control consisted of plasma incubated with TBS alone. For the 
study of neutralization, 100 μL of mixtures containing a fixed dose of 
venom and various dilutions of antivenom were prepared, and incu-
bated at 37 �C for 30 min (Gen�e et al., 1989). Then, each mixture, 
containing a venom dose corresponding to 2 Minimum Coagulant Doses 
(MCDs), were tested for coagulant activity as described above. A control 
group was included, corresponding to plasma incubated with venom 
that was previously incubated with PBS instead of antivenom. Changes 
in absorbance were recorded and neutralization was expressed as 
Effective Dose (ED), corresponding to the ratio of venom/antivenom in 
which the change in absorbance is prolonged three times as compared to 
plasma incubated with venom alone. 
2.5.2. Phospholipase A2 (PLA2) activity 
The titrimetric method described by Dole (1956) and Guti�errez et al. 
(1986) was followed, using egg yolk phospholipids as substrate. Various 
venom doses were prepared in triplicate for each venom, and 100 μL of 
each solution was placed in 1 mL of egg yolk diluted 1:5 in a solution of 
0.1 M Tris, 0.01 M CaCl2 and 1% Triton X-100 (pH 8.5). Mixtures 
comprising various ratios of mg venom/mL antivenom were incubated 
at 37 �C for 30 min. Free fatty acids were extracted and titrated. Activity 
was expressed as μEq fatty acid released per mg protein per min. For 
neutralization, mixtures were prepared containing a fixed amount of 
venom (25 μg) and variable dilutions of antivenom. Controls included 
venom incubated with PBS instead of antivenom. After an incubation of 
30 min at 37 �C, the PLA2 activity of the mixtures was assessed as 
described. Neutralization was expressed as Median Effective Dose 
(ED50), corresponding to the ratio of venom/antivenom in which PLA2 
activity was reduced by 50% as compared to the activity of venom alone. 
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2.5.3. Proteinase activity 
Proteinase activity was assessed on azocasein following the method 
described by Guti�errez et al. (2008). Briefly, various amounts of venom 
dissolved in 20 μL of PBS, were added to 100 μL of substrate (10 mg/mL 
azocasein dissolved in 25 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 7.4), 
followed by incubation at 37 �C for 90 min. Reactions were stopped by 
the addition of 200 μL of 5% trichloroacetic acid. Then, 150 μL of each 
supernatant were mixed with 150 μL of 0.5M NaOH, and the absorbance 
at 450 nm was recorded. Proteolytic activity was expressed as units/mg 
venom, one unit corresponding to a change in absorbance of 0.2/min. 
For neutralization, mixtures were prepared containing a fixed amount of 
venom (8 μg) and variable dilutions of antivenom. The antivenom ED50 
was expressed as the ratio of μL of antivenom/mg venom (or mg ven-
om/mL antivenom) at which the response of the control of venom is 
reduced 50% (Guti�errez, 2018). 
2.5.4. Third-generation antivenomics 
Third-generation antivenomics (Pla et al., 2017; Calvete et al., 2018) 
was applied to compare the specific immunoreactivity of the anti-Mlt 
antivenom (Uzbiopharm®, Uzbekistan) and the paraspecific immuno-
reactivity of the anti-Vbb antivenom (Microgen®, Russia) (Al-Shekhadat 
et al., 2019) towards the venom of M. lebetina obtusa from Republic of 
Dagestan (Russian Federation). To this end, the antivenoms were dia-
lyzed against MilliQ® water, lyophilized, and 122 mg (anti-Mlt) and 
116 mg (anti-Vbb) of total lyophilizate weight were reconstituted in 3 
mL of 0.2 M NaHCO3, 0.5 M NaCl, pH 8.3 (coupling buffer). The con-
centrations of these antivenom stock solutions were determined spec-
trophotometrically using an extinction coefficient for a 1 mg/mL 
concentration (ε0.1%) at 280 nm of 1.36 (mg/mL)  1 cm  1 (Howard and 
Kaser, 2014). Antivenom affinity columns were prepared in batch. To 
this end, 3 mL of CNBr-activated Sepharose™ 4B matrix (Ge Healthcare, 
Buckinghamshire, UK) packed in a ABT column (Agarose Bead Tech-
nologies, Torrej�on de Ardoz, Madrid) and washed with 15x matrix 
volumes of cold 1 mM HCl, followed by two matrix volumes of coupling 
buffer to adjust the pH of the column to 8.0–9.0. CNBr-activated instead 
of N-hydroxysuccinimide (NHS)-activated matrix was employed 
because NHS released during the coupling procedure absorbs strongly at 
280 nm, thus interfering with the measurement of the concentration of 
antibodies remaining in the supernatant of the coupling solution. The 
antivenom stock solutions in 3 mL of coupling buffer were incubated 
with 3 mL CNBr-activated matrix for 4 h at room temperature. Anti-
venom coupling yields, estimated measuring A280nm before and after 
incubation with the matrix, were 80.2 mg (anti-Mlt) and 85.5 mg 
(anti-Vbb) (F(ab’)2 (i.e. 26.7 mg anti-Mlo and 28.5 mg anti-Vbb/mL 
CNBr-activated Sepharose™ 4B matrix). After the coupling, remaining 
active matrix groups were blocked with 3 mL of 0.1 M Tris-HCl, pH 8.5 
at room temperature for 4 h. Affinity columns, each filled with 280 μL 
(anti-Vbb) or 300 μL (anti-Mlt) of affinity matrix containing 8 mg of 
Fig. 1. Proteomic analyses of venom of the Dagestan blunt-nosed viper, Macrovipera lebetina obtusa. Panel A, reverse-phase chromatographic separation of the 
venom proteins. Panel B, SDS–PAGE profile of the chromatographic fractions analyzed under non-reduced (upper gels) and reduced (lower gels) conditions. Panel C, 
pie chart displaying the relative occurrence (in percentage of total venom proteins) of toxins from different protein families in the venom proteome. SVMPi, tripeptide 
inhibitors of snake venom metalloproteinases; BPP, Bradykinin potentiating peptides; DISI, disintegrin; DC, disintegrin-like/cysteine-rich fragment of SVMP of class 
PIII; D49-PLA2, D49 phospholipases A2; CRISP, cysteine-rich secretory protein; SVSP, snake venom serine proteinase; PI- and PIII-SVMP, metalloproteinases of class 
PI and PIII, respectively; CTL, C-type lectin-like protein; 50NT, 50-nucleotidase; LAO, L-amino acid oxidase; PDE, phosphodiesterase; Hyal, hyaluronidase. na, not 
assigned venom component. 
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immobilized F(ab’)2 molecules, were alternately washed with three 
matrix volumes of 0.1 M acetate containing 0.5 M NaCl, pH 4.0–5.0, and 
three matrix volumes of 0.1 M Tris-HCl, pH 8.5. This procedure was 
repeated 6 times. The columns were then equilibrated with 3 vol of 
working buffer (PBS, 20 mM phosphate buffer, 135 mM NaCl, pH 7.4) 
and incubated with increasing amounts (100–1200 μg of total venom 
proteins) of M. l. obtusa dissolved in ½ matrix volume of PBS, and the 
mixtures incubated for 1 h at 25 �C in an orbital shaker. As specificity 
controls, 300 μL of CNBr-activated Sepharose™ 4B matrix, without 
(mock) or with 8 mg of immobilized control (naïve) horse IgGs, were 
incubated with venom and developed in parallel to the immunoaffinity 
columns. The non-retained eluates of columns incubated with 100–300, 
600, 900, and 1200 μg of venom were recovered, respectively, with 3x, 
5x, 7x, and 9x matrix volume of PBS, and the immunocaptured proteins 
were eluted, respectively, with 3x (100–300 μg) and 6x (600–1200 μg) 
matrix volume of 0.1M glycine-HCl, pH 2.7 buffer, and brought to 
neutral pH with 1M Tris-HCl, pH 9.0. The entire fractions eluted in 
100–300 μg, ½ of the fractions recovered in 600 μg, 1 =3 of the 
non-retained fractions and ½ of the retained fractions recovered in 900 
μg, ¼ of the non-retained fractions and ½ of the retained fractions 
recovered in 1200 μg, were concentrated in a Savant SpeedVac™ vac-
uum centrifuge (ThermoFisher Scientific, Waltham, MA USA) to 45 μL, 
40 μL of which were then fractionated by reverse-phase HPLC using an 
Agilent LC 1100 High Pressure Gradient System (Santa Clara, CA, USA) 
equipped with a Discovery® BIO Wide Pore C18 (15 cm � 2.1 mm, 3 μm 
particle size, 300 Å pore size) column and a DAD detector. The column 
was developed at a flow rate of 0.4 mL/min with a linear gradient of 
0.1% TFA in MilliQ® water (solution A) and 0.1% TFA in acetonitrile 
(solution B), isocratic (5% B) for 1 min, followed by 5–25% B for 5 min, 
25–45% B for 35 min, and 45–70% B for 5 min. Protein detection was 
carried out at 215 nm with a reference wavelength of 400 nm. The 
fraction of non-immunocaptured molecules was estimated as the rela-
tive ratio of the chromatographic areas of the toxin recovered in the 
non-retained (NR) and retained (R) affinity chromatography fractions 
using the equation %NRi ¼ 100-[(Ri/(Ri þ NRi)) x 100], where Ri 
corresponds to the area of the same protein “i" in the chromatogram of 
the fraction retained and eluted from the affinity column. However, for 
some toxins that were poorly recovered in the column-retained fraction 
owing to their high binding affinity to the immobilized antivenom likely 
preventing their elution from the column (Calvete et al., 2015), the 
percentage of non-immunocaptured toxin“i” (% NRtoxin“i”) was 
calculated as the ratio between the chromatographic areas of the same 
peak recovered in the non-retained fraction (NRtoxin“i”) and in a 
reference venom (Vtoxin“i”) containing the same amount of total pro-
tein that the parent venom sample and run under identical chromato-
graphic conditions, using the equation %NRtoxin“i” ¼
(NRtoxin“i”/Vtoxin“i”) x 100. The percentage of antivenom anti-toxin F 
(ab’)2 molecules was calculated by dividing [(1/2 maximal amount (in 
μmoles) of total venom proteins bound per antivenom vial) x molecular 
mass (in kDa) of antibody (F(ab’)2, 110 kDa) molecule] by the [total 
amount of antibody (F(ab’)2) (in mg) per antivenom vial (Calvete et al., 
2018; Sanz et al., 2018; Al-Shekhadat et al., 2019). Binding saturation 
was computed by extrapolation from data modelled in Excel to degree 2 
polynomial functions. 
3. Results and discussion 
3.1. The Dagestan blunt-nosed viper, Macrovipera lebetina obtusa, venom 
proteome 
The venom proteome of M. l. obtusa (Dagestan, Russia) was charac-
terized and quantified by applying the previously described (Calvete, 
2014; Eichberg et al., 2015) two-step pre-MS decomplexation protocol 
(reverse-phase HPLC and SDS-PAGE) followed by peptide-centric bot-
tom-up analysis of tryptic digests of the electrophoretically-separated 
protein bands eluted in the different reverse-phase chromatographic 
fractions. Supplementary Table S1 shows the details of the MS/MS 
assignment, quantification and database matching of the proteins eluted 
in the 40 reverse-phase chromatographic fractions (Fig. 1A) and further 
resolved by SDS-PAGE of each chromatographic fraction (Fig. 1B). The 
venom proteome of the Dagestan blunt-nosed viper comprised a com-
plex arsenal of peptides and proteins derived from precursor proteins 
encoded by genes belonging to 11 different families (Fig. 1C). 
Endogenous tripeptide inhibitors of SVMPs (SVMPi) and bradykinin- 
potentiating peptides (BPPs) are released into the venom proteome by 
the proteolytic processing of a common precursor (Graham et al., 2005; 
Cidade et al., 2006). These peptide components comprise, respectively, 
4.8% and 5.6% of the Dagestan blunt-nosed viper venom proteome 
(Fig. 1C). SVMPi regulate the proteolytic activities of SVMPs in a 
reversible manner under physiological conditions, thus protecting 
glandular tissues and venom factors from the proteolytic activity of 
SVMPs stored at high concentration in an inactive but competent state 
for many months in the lumen of the venom gland of many Viperidae 
snakes (Huang et al., 1998, 2002; Munekiyo and Mackessy, 2005; 
Wagstaff et al., 2008). Bradykinin-potentiating peptides are inhibitors of 
the angiotensin I-converting enzyme, which enhance the hypotensive 
effect of the circulating bradykinin, contributing to cardiovascular shock 
in the snake’s prey or human victim (Ferreira et al., 1970; Greene et al., 
1972; Luft, 2008). Among the venom proteins, snake venom Zn2þ-de-
pendent metalloproteinases of the PI and PIII classes, which comprise, 
respectively, 14.6% and 9.4% of the venom proteome (Fig. 1C), along 
with proteolytic product comprising the C-terminal disintegrin-like and 
cysteine-rich domains of PIII-SVMPs (DC-fragments, 0.6%), and 
medium-sized and dimeric disintegrins released from PII-SVMP pre-
cursors (~3.5% of Mlo venom proteome), (Fox and Serrano, 2005; 
Ju�arez et al., 2008; Carbajo et al., 2015), represent the most abundantly 
expressed (~28% of the total venom proteome) gene family in the 
Dagestan blunt-nosed viper venom proteome (Fig. 1C). Other major 
venom toxin families are, in order of relative abundance, venom serine 
proteinases (SVSP, 23.4%) (Swenson and Markland, 2005; Serrano, 
2013), phospholipases A2 (PLA2, 13.6%) (Koludarov et al., 2019), 
C-type lectin-like proteins (CTL, 8.7%) (Clemetson, 2010; Arlinghaus 
and Eble, 2012), and proteoforms of obtustatin (short DISI, 7.4%), a 
short disintegrin that express the lysine-threonine-serine (KTS) α1β1 
integrin inhibitory tripeptide in its active loop (https://www.ncbi.nlm. 
nih.gov/protein/P83469) (Marcinkiewicz et al., 2003) (Fig. 1C). The 
remaining 18.4% of the venom proteome is constituted by 6 toxin 
classes, none of which exceeds 2% relative abundance (Fig. 1C). This set 
of minor toxins include homo and hetero dimeric disintegrins VLO4 
[P0C6A8] and VLO5 [P0C6A9, P0C6B0] encoded by short-coding 
messages (Okuda et al., 2002; Calvete et al., 2003; Sanz et al., 2008); 
cysteine-rich secretory protein (CRISP); 50-nucleotidase (50NT); L-amino 
acid oxidase (LAO); phosphodiesterase (PDE); and hyaluronidase (Hyal) 
(Sanz et al., 2008; Siigur et al., 2019). 
The complex toxin arsenal of M. lebetina obtusa venom may prevent 
blood coagulation (serine proteinases) and platelet aggregation (dis-
integrins, C-type lectin-like proteins, and L-amino acid oxidase); exert 
hemolytic and myotoxic effects (phospholipases A2); and disrupt the 
extracellular matrix of the vascular subendothelium (Zn2þ-dependent 
metalloproteinases). These pharmacological activities may account for 
the severe pain at the bite site, nausea and vomiting, swelling, necrosis 
and systemic disseminated hemostatic manifestations reported in 
human envenomings inflicted by M. l. obtusa (Corkill, 1932; Sharma 
et al., 2008; Warrell, 2010; Zamani et al., 2016). 
3.2. Toxic and enzymatic activities of M. L. obtusa venom and their 
neutralization by Uzbiopharm® and Microgen® antivenoms 
In the murine model, the venom of M. l. obtusa (Dagestan, Russia) 
was lethal at a Median Lethal Dose (LD50) of 34.95 (95% CI, 
18.98–54.93) μg/mouse (Table 1). The venom also exhibited Minimum 
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Table 1 
Toxic effects of Macrovipera lebetina obtusa venom (V) in mice and their neutralization by the monospecific anti-Mlt antivenom (AV) from Uzbiopharm® and the 
monospecific anti-Vbb Microgen® antivenom.a 95% confidence limits are expressed in parentheses. Other results are presented as mean � S.D; NA, not analyzed.  
Toxic activity Neutralization by antivenom 
Uzbiopharma Ltd. (Uzbekistan) Microgen (Russia) 
μL AV/mg V mg V/mL AV μL AV/mg V mg V/mL AV 
Lethality (i.p.) [mg/mouse] 34,95 (18,98–54,93)a 518 (345–847)a 1,93 (1,18–2,90)a 424 (295–971)a 2,36 (1,03-3,39)a 
Hemorrhagic (MHD) [mg/mouse] 0,18 � 0,10 2168 � 325 0,47 � 0,06 478 � 14 2,09 � 0,06 
PLA2 activity [μeq/mg/min] 9,84 � 0,34 639 � 63 1,57 � 0,15 217 � 13 4,61 � 0,27 
Proteinase [U/mg] 2,13 � 0,21 872 � 68 1,15 � 0,01 994 � 12 1,01 � 0,08 
Procoagulant (MCD) [μg/mouse] 0,20 � 0,00 264 � 23 3,80 � 0,31 1979 � 90 0,51 � 0,02 
Defibrinogenic (MDD) Null up to 20 μg NA NA NA NA  
Table 2 
Concentration-dependent immunoretained (RET) Macrovipera lebetina obtusa (Mlo) venom proteins by Uzbiopharm® (Uzbekistan) anti- 
Mlt antivenom affinity column. Maximal binding for each RP-HPLC fraction is highlighted in bold face and grey background. 
D. Pla et al.                                                                                                                                                                                                                                      
Toxicon: X 6 (2020) 100035
7
Hemorrhagic Dose (MHD) of 0.18 � 0.10 μg/mouse, but it did not show 
defibrinogenating activity when up to 20 μg were injected intrave-
nously, the highest non-lethal dose tested (Table 1). In in vitro assays, the 
venom showed phospholipasic, proteolytic, and coagulant activities 
(Table 1). Both, the monospecific anti-Mlt antivenom from Uzbio-
pharm® and the Microgen® monospecific anti-Vbb antivenom were 
capable of neutralizing, with similar efficacy, venom lethality (Table 1). 
The calculated lethality neutralization potencies (P, the amount (mg) of 
venom completely neutralized per mL of antivenom) for Uzbiopharm® 
anti-Mlt and anti-Vbb Microgen® antivenoms were 1.46 and 1.77. These 
figures indicate that 1 mL of Uzbiopharm® and Microgen® antivenoms 
may protect mice from 41 to 50 LD50s of Mlo venom, respectively. For 
comparison, the ED50 of a monospecific F(ab’)2 antivenom produced at 
Razi Institute (Tehran, Iran) was 2.2 � 0.4 mg/mL (Latifi et al., 1978; 
Latifi, 1984). This value is similar to the ED50s determined for the 
Uzbiopharm® (1.93 (95%CI 1.18–2.90) mg/mL) and Microgen® (2.36 
(95%CI 1.03–3.39) mg/mL) antivenoms (Table 1). However, since the 
authors did not report the number of LD50 used in the determination of 
the ED50, it is not possible to calculate the potency of Razi antivenom. A 
new polyvalent equine F(ab’)2 antivenom (Inoserp Europe) designed to 
treat envenoming by snakes in the Eurasian region, generated against a 
mixture of venoms from the European vipers V. ammodytes, V. aspis, 
V. berus, V. latastei, Montivipera xanthina, Macrovipera schweizeri, M. l. 
obtusa, M. l. cernovi, and M. l. turanica (García-Arredondo et al., 2019), 
showed an intravenous ED50, against 5 LD50s of M. l. obtusa (Azerbaijan) 
venom (LD50 ¼ 16.32 (15.73–16.93) μg/mouse), of 3.47 (95% CI 
Table 3 
Concentration-dependent immunoretained (RET) Macrovipera lebetina obtusa (Mlo) venom proteins by Microgen® (Russia) anti-Vbb 
antivenom affinity column. Maximal binding for each RP-HPLC fraction is highlighted in bold face and grey background. 
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3.38–3.56) mg/mL, which translates into a calculated P of 2.13 mg/mL 
(Supplementary Table S2). This figure indicates that 1 mL of Inoserp 
Europe may protect mice against 130.5 and 61 LD50s of Mlo from 
Azerbaijan and Dagestan venom, respectively. However, given the 
marked difference between the LD50s reported for Mlo venom from Iran 
(i.v., 9.4–22.5 μg/mouse of 16–18 g body weight (Latifi, 1984); i,v., 
18.4 � 1.4 μg/mouse of 16–18 g body weight (Kurtovi�c et al., 2014); 
Azerbaijan (i.v., 15.73–16.93 μg/mouse of 18–20 g body weight) (Gar-
cía-Arredondo et al., 2019) and Dagestan (i.p., 18.98–54.93 μg/mouse 
of 18–20 g body weight) (this work), differences in mean body weight of 
mice, and different administration route, a comparison between anti-
venoms produced by Razi Institute, Inoserp Europe, Uzbiopharm® and 
Microgen® should be interpreted cautiously. 
Uzbiopharm® anti-Mlt and Microgen® anti-Vbb antivenoms were 
also effective neutralizing the in vivo and in vitro toxic effects of Dagestan 
blunt-nosed viper venom. However, whereas the homolog antivenom 
from Uzbiopharm® performed better blocking the procoagulant and 
proteolytic activities, heterologous Microgen® antivenom was more 
effective reversing the venom’s hemorrhagic and PLA2 activities 
(Table 1). 
3.3. Third-generation antivenomics: quantification of venom-specific 
antivenom antibodies 
A third-generation antivenomics (3GA) approach was applied to 
quantify, in a concentration-dependent and toxin-resolved manner, the 
immunorecognition landscape of the Uzbiopharm® and Microgen® 
antivenoms towards M. l. obtusa (Dagestan, Russia) venom. The results 
displayed, respectively in Tables 2 and 3 and Supplementary Tables S3 
and S4, show that excepting for the poorly-immunogenic peptides eluted 
in the first fractions of the reverse-phase chromatogram, both anti-
venoms efficiently immunocaptured all the major venom proteins 
(Fig. 2, panels A and B). 
Affinity columns containing 8 mg anti-Mlt of F(ab’)2 antibodies of 
Uzbiopharm® antivenom had maximal binding capacity of 227.88 μg M. 
lebetina obtusa venom proteins (e.g. 28.49 mg venom/g antivenom). 
Since the protein concentration of the batch of anti-Mlt used was 98 mg/ 
mL and a vial contained 9.4 mL, the maximal binding capacity per vial 
was 26.24 mg M. l. obtusa venom proteins. Considering an average 
molecular mass for Mlo toxins of 29.8 kDa (calculated as Σ (% i x Mi), 
where % i is the relative abundance of toxin “i” and Mi its molecular 
mass in Da), 26.24 mg of M. l. obtusa venom proteins equals 0.88 μmoles 
of venom molecules. Assuming that one or both antigen-binding sites of 
an F(ab’)2 molecule were occupied at maximal antigen binding capacity, 
one vial of Uzbiopharm® anti-Mlt antivenom contained, respectively 
0.88 μmoles (96.85 mg) or 0.44 μmoles (48.42 mg) of toxin-binding 
molecules. This figures correspond, respectively, to 10.5% and 5.25% 
of the total Uzbiopharm® anti-Mlt F(ab’)2 molecules. 
Affinity columns containing 8 mg of immobilized Microgen® anti-
venom F(ab’)2 molecules had capacity to immunoretain 165.02 μg of 
M. l. obtusa venom proteins (20.63 mg venom/g antivenom). Bearing in 
mind that the vials of this antivenom are manufactured with 1.3 mL of 
85 mg F(ab’)2/mL (110.5 mg F(ab’)2/vial), the 3GA outcome indicated 
for Microgen® antivenom a maximal binding capacity of 2.68 mg (0.088 
μmoles) M. l. obtusa venom proteins per vial. This result translates into 
an estimate of between 4.32% (both Ag binding site occupied) and 
8.68% (one Ag binding site occupied) of total vial’s F(ab’)2 molecules 
bearing paraspecificity towards M. l. obtusa toxins. 
3.4. Quantification of lethality neutralizing through combination of in 
vivo and in vitro preclinical data 
The ability to bind toxins is a necessary but not sufficient molecular 
property to endow an antivenom with clinical utility. The percentage of 
lethality neutralizing antibodies can be calculated as the ratio between 
the antivenom potency and its maximum toxin binding capacity, both 
terms expressed as mg venom/vial. This parameter was (13.72/26.24) x 
100 ¼ 52.3% for Uzbiopharm® anti-Ml antivenom and (2.3/2.68) x 100 
¼ 85.8% for Microgen® anti-Vbb antivenom. This means that 52.3% of 
the 5.25–10.5% Uzbiopharm® anti-Mlt F(ab’)2 molecules that recognize 
M. l. obtusa venom toxins (i.e. 2.75–5.49% of the total Uzbiopharm® 
anti-Mlt F(ab’)2 molecules) represent clinically relevant antibodies. For 
Microgen® anti-Vbb, 3.71–7.45% of the total antivenom F(ab’)2 mole-
cules are potential live-saving antibodies. If the preclinical data are 
confirmed in clinical studies, the treatment of a M. l. obtusa bite, which 
can deliver up to 90 mg of venom (Latifi, 1984), would nominally 
require up to 42 (Inoserp Europe), 51 (Microgen® anti-Vbb) or 62 
(Uzbiopharm® anti-Ml) mL of antivenom. 
Fig. 2. Comparative immunorecognition ability of the anti-Mlt (Uzbio-
pharm®) and anti-Vbb (Microgen®) antivenoms towards Macrovipera 
lebetina obtusa venom toxins. Third-generation antivenomic analyses of anti- 
Mlt (panel A) and anti-Vbb (panel B) antivenoms challenged with increasing 
concentration of M. l. obtusa venom. Reverse-phase chromatographic analysis of 
whole M. l. obtusa venom (panels a) and of the non-retained and the immu-
noretained fractions recovered from affinity column (8 mg immobilized anti-
venom F(ab’)2 molecules) incubated with increasing amounts (100–1200 μg) of 
venom from M. l. obtusa from Dagestan (Russian Federation) are displayed in 
panels b through i. Panels j–l show reverse-phase HPLC separations of the 
retained and non-retained venom fractions on mock matrix and naïve equine 
IgG affinity columns, respectively. 
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4. Concluding remarks 
This paper illustrates the analytical power of combining venomics, 
third-generation antivenomics, and neutralization assays of the lethal 
and toxic venom activities to assess the preclinical efficacy of anti-
venoms. Here, we show that the monospecific anti-Vipera berus berus 
antivenom from Microgen® (Russia) displays remarkable para-
specificity towards the toxins of Dagestan blunt-nosed viper venom. 
Analogously, Kurtovi�c and co-workers have also reported that the Vipera 
ammodytes-specific antivenom (European viper venom antiserum, 
Institute of Immunology, Zagreb, Croatia) is preclinically effective in 
neutralizing lethal toxicity and hemorrhagic activity of venoms of 
Armenian mountain snakes – Montivipera raddei and M. l. obtusa. 
(Kurtovi�c et al., 2014). This evidence points to a notable degree of 
conservation of immunogenic determinants between European and 
Oriental vipers since their geographic segregation during the early 
Miocene (23.3–16.3 million years ago) (R€ogl and Steininger, 1983; 
Szyndlar and Rage, 1999; Lenk et al., 2001; Garrigues et al., 2005). 
Kurtovi�c et al. (2014) reported a protective efficacy for different 
batches of Zagreb V. ammodytes-specific antivenom (R, defined as the 
number of LD50 doses that can be neutralized per mL of undiluted 
serum) of 47.8 � 20 to 135 � 21.5 Mlo i. v. LD50s/mL. This range 
overlaps in its lower limit with the neutralizing capacity of the Micro-
gen® anti-Vbb antivenom. However, the potency of the anti-Vbb anti-
venom could nominally be improved 11.5–23 times by affinity 
chromatographic purification of its F(ab’)2 antibodies showing para-
specificity against M. l. obtusa (Dagestan) venom toxins. 
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